Stay updated with breaking news from Marinus Pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.
12.12.2023 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and ... Seite 1
/PRNewswire/ -- The "Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of...
Genprex (NASDAQ:GNPX – Get Rating) and Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations. Earnings and Valuation This table compares Genprex and Marinus Pharmaceuticals’ […]
Genprex (NASDAQ:GNPX – Get Rating) and Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations. Volatility & Risk Genprex has a beta of -0.35, meaning […]